Jump to content

HVTN 702

From Wikipedia, the free encyclopedia

HVTN 702 was a clinical trial which the HIV Vaccine Trials Network organized to develop an HIV vaccine. In February 2020 the organizers halted the trial after finding no evidence of efficacy.[1][2][3]

Around December 2019 various media outlets reported that HVTN 702 could be an effective vaccine in preventing HIV.[4][5]

In 2016 various media outlets announced the start of the research.[6][7][8]

HVTN 702 was based on outcomes of the RV 144 trial.[9]

References

[edit]
  1. ^ Doughton, Sandi (3 February 2020). "'Incredibly disappointing': Fred Hutch, feds end HIV vaccine trial after data shows no benefit". The Seattle Times.
  2. ^ "Experimental HIV vaccine regimen ineffective in preventing HIV". National Institutes of Health (NIH). 3 February 2020.
  3. ^ Russell, Sabin (4 February 2020). "Promising HIV vaccine fails to show efficacy, trial halted". Fred Hutch.
  4. ^ Fitzsimons, Tim (1 December 2019). "HIV vaccine in 2021? Leading experts 'optimistic' about ongoing trials". NBC News.
  5. ^ Lee, Bruce Y. (3 December 2019). "An HIV Vaccine By 2021? Here Is What Needs To Happen". Forbes.
  6. ^ "New HIV vaccine trial to start in South Africa". www.cbsnews.com. 28 November 2016.
  7. ^ Galeon, Dom (29 November 2016). "An End to AIDS: New Vaccine Could Be The "Final Nail in the Coffin" for HIV". Futurism.
  8. ^ "HIV vaccine trial begins in South Africa". BBC News. 30 November 2016.
  9. ^ Cairns, Gus (26 July 2017). "Another HIV vaccine efficacy trial will start this year". Aidsmap.
[edit]